News Release

Printer Friendly Version View printer-friendly version
Download PDF PDF Format
<< Back
NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017

REHOVOT, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 10:30 am PT / 1:30 pm ET in San Francisco.  Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.

To access the live webcast of the presentation, please visit  A replay will be available for a limited time following the presentation.

About NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration.  The Company has three product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease.  The Company has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD.  The LD/CD product candidate in low dose and high dose form (ND0612L and ND0612H), are used for the treatment of moderate and advanced Parkinson’s disease patients, respectively, and are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD.  NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.

NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
Tel.: +972-8-946 2729;
Cell: +1-617-517 6077

U.S. Investor Contact:
David Carey
Lazar Partners Ltd.

Primary Logo

NeuroDerm Ltd.